Discovery and surveillance
VDEC’s Discovery and surveillance capabilities provide unique services across a spectrum of molecular immunology platforms.
Latest change: Added the VDEC form link.
AI Summary
The Vaccine Development and Evaluation Centre (VDEC), a division of the UK Health Security Agency (UKHSA), provides specialized scientific expertise and regulated facilities to advance the development and assessment of vaccines and therapeutics. VDEC supports a broad range of stakeholders, including industry, academia, and government, by focusing on pathogen classification, disease mechanisms, and national surveillance. The center utilizes multidisciplinary teams in serology, immunology, and pathology to assist in both pre-clinical and clinical evaluation phases. Notable contributions include serological surveillance for the COVID-19 pandemic, rapid assay development for outbreaks such as Mpox and H5N1, and support for tuberculosis vaccine development through non-human primate studies. Although this document serves as an overview of capabilities rather than a regulatory inspection report—and thus does not list specific violations or inspection dates—it highlights VDEC's commitment to operating within a regulated framework to maintain standardized procedures. By fostering collaboration and developing flexible reactive protocols, VDEC strengthens global preparedness for future health emergencies. Organizations are encouraged to contact UKHSA to utilize these diagnostic and evaluative services for vaccine innovation.
The full document, source attachments, and change history are available on KeyPedia. Sign in to view.